Related Experiment Video

Updated: Jun 23, 2026

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis
07:24

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis

Published on: February 6, 2021

Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab

S H Lee1, S J Woo, K H Park

  • 1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.

Eye (London, England)
|May 2, 2009
PubMed
Abstract

Insights

Acute endophthalmitis is a rare complication of intravitreal bevacizumab injections (IVBI), occurring in 0.099% of cases. Contaminated aliquot drug from compounding pharmacies can cause Serratia marcescens infections, leading to devastating outcomes.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmaceutical Science

Background:

  • Intravitreal bevacizumab injections (IVBI) are common for treating retinal diseases.
  • Assessing the incidence of endophthalmitis post-IVBI is crucial for patient safety.

Observation:

  • Two cases of Serratia marcescens endophthalmitis were identified following IVBI.
  • The incidence of endophthalmitis after 2020 IVBIs was 0.099%.

Findings:

  • S. marcescens, identified via molecular typing, was the causative agent in both cases.
  • Contamination likely occurred during the aliquot preparation process at a compounding pharmacy.

Implications:

  • Hospital compounding pharmacies may not guarantee sterility of aliquot drugs for IVBI.
  • Serratia endophthalmitis can have severe visual consequences despite treatment.
  • Strict protocols for drug preparation and handling are essential to prevent post-injection infections.

More Related Videos

Intracameral Injection in Rats with Low Risk of Adverse Effects06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...